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Angiogenesis in tumor development
CanCer Cells are Cells that have lost their capacity to di-
vide in a controlled manner. They give rise to a neoplastic 
lesion that is supported by stromal cells. Both tumor cells 
and stromal cells contribute structurally and functionally to 
tumor development. Nevertheless, the tumor mass is typi-
cally limited to a size of 1–2 mm³, because further growth 
requires the diffusion of adequate amounts of oxygen and 
essential nutrients. To meet this demand, tumors induce 
the growth of blood vessels, a process referred to as angio-
genesis, by up-regulating the expression and secretion of 
growth factors such as vascular endothelial growth factor 
(VEGF), fibroblast growth factors (FGFs), angiopoietins 
(Ang), placental growth factor (PlGF), and some integrins, 
and concomitantly down-regulating several anti-angiogenic 
factors [22]. In addition, angiogenesis coincides with in-
creased circulating tumor cells, facilitating metastatic 
Summary. Tumor progression requires the activation of neovascularization, or angiogenesis, 
a process orchestrated by tumor and by stromal cells within the tumor mass. In the thera-
peutic targeting of angiogenesis, the aim is to inhibit tumor growth and progression. In-
deed, anti-angiogenic therapy is currently used in several types of cancer. Nevertheless, 
both the tumor cells and the stromal components may be variably resistant to anti-angio-
genic therapy, demonstrating refractoriness, or intrinsic resistance, on the one hand, and 
acquired resistance, gained progressively during treatment, on the other. Several strategies 
have been proposed to overcome both types of resistance but they remain to be tested in 
preclinical studies and clinical trials.
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Resum. La progressió dels tumors requereix l’activació d’una neovascularització, o angiogè-
nesi, un procés orquestrat per les cèl·lules tumorals i per l’estroma dins la massa tumoral. La 
inhibició terapèutica d’aquest procés té per objectiu impedir el creixement i la progressió 
del tumor. Actualment la terapèutica antiangiogènica s’aplica en determinats tipus de càn-
cer. No obstant això, hi ha cèl·lules tumorals i components estromals que poden presentar 
una resistència variable a la terapèutica antiangiogènica, que pot ser refractarietat o resistèn-
cia intrínseca, per una banda, o resistència adquirida progressivament al llarg del tracta-
ment, per una altra. S’han proposat diverses estratègies per lluitar contra aquests dos tipus 
de resistència, però encara han de provar-se en estudis preclínics i en assajos clínics.
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in hyperactivation of the HIF signaling pathway and tran-
scription of the genes encoding its downstream effectors 
[30,36]. Therefore, the therapeutic use of molecules that 
inhibit binding to, e.g., VEGF, glucose transporter GLUT1, 
transforming growth factor-α, and platelet-derived growth 
factor (PDGF) receptors, has been investigated in many 
types of tumors [43,44].
Anti-angiogenic strategies
Discovery of the dependence of tumor growth on angiogen-
esis and the stromal contribution to new vessel formation 
suggested new therapeutic targets. Targeting of the cells that 
support tumor growth rather than the cancer cells them-
selves is a relatively recent approach in cancer therapy, one 
that is particularly promising because these cells are geneti-
cally stable and therefore less likely to accumulate mutations 
that allow them to rapidly develop drug resistance. In 1971, 
Judah Folkman proposed the inhibition of angiogenesis as a 
therapeutic strategy for cancer. Subsequently, several anti-
angiogenic drugs aimed at inhibiting endothelial cell growth 
were developed. More recently, other cell types in the tumor 
microenvironment, either instead of or together with endo-
thelial cells, have been targeted. These cells include peri-
cytes, which contribute to vascular maturation by releasing 
signals that maintain endothelial cell survival and structural-
ly support the vessel wall [12] (Fig. 1).
Based on their mechanism of action, anti-angiogenic 
drugs can be classified in two groups. (1) Direct-acting drugs 
that prevent vascular endothelial cells from proliferating, mi-
grating, or avoiding cell death in response to a spectrum of 
pro-angiogenic proteins, including VEGF, bFGF, interleu-
kin-8, and PDGF. In addition to the VEGF-blocking antibody 
bevacizumab, for use in combination with chemotherapy in 
patients with metastatic colorectal cancer, metastatic breast 
cancer, and other cancers, the U.S. FDA has approved chemi-
cal inhibitors of VEGF receptor 2 (VEGFR2), such as suni-
tinib and sorafenib, as first-line monotherapy for metastatic 
kidney cancer. (2) Indirect-acting drugs that secondarily 
either prevent the expression or block the activity of tumor 
proteins that activate angiogenesis. The targets of the latter 
group are the tumor-cell signaling pathways responsible for 
the synthesis or secretion of pro-angiogenic molecules. A typ-
ical example is mTOR inhibitors, which act on tumor-cell 
survival pathways and secondarily decrease VEGF expres-
sion, thereby indirectly exerting an anti-angiogenic effect.
In this review we discuss direct-acting anti-angiogenic 
drugs, which for the most part inhibit pro-angiogenic signal-
ing pathways. Consistent with its role as the main promoter 
of angiogenesis, VEGF is the primary target of the currently 
approved anti-angiogenic drugs, which include monoclonal 
antibodies and selective inhibitors of kinase activity [22].
spread. There is also evidence that angiogenesis precedes 
tumor formation, which implies that it is the rate-limiting 
step not only for tumor growth but also much earlier, for 
tumor development [5]. 
Tumor cells cooperate with other cell types in the tu-
mor microenvironment, such as immune cells, inflamma-
tory cells, hematopoietic cells, and stromal fibroblasts. 
These cells then secrete various types of inducers, which 
activate endothelial cells and therefore angiogenesis [6]. In 
1986, Dvorak described the inflammatory phenotype of tu-
mors as “wounds that never heal.” In the tumor mass, the 
balance is tipped in favor of angiogenesis, with the newly 
formed vasculature able to oxygenate and nourish the 
growing neoplasm. 
The imbalance resulting in the sustained production of 
pro-angiogenic factors, together with the persistent lack of 
vascular stabilizing factors, leads to the formation of an im-
mature and dysfunctional vascular system that cannot keep 
pace with the rapid growth of the tumor mass. Therefore, 
the vascular tree in a tumor is typically chaotic, with dead-
end vessel branches and areas of inverted and intermittent 
blow flow, which may impair vascular function and lead to 
regions of lowered perfusion and hypoxia. The latter in 
turn causes up-regulation of the transcription factor hy-
poxia-inducible factor (HIF) and therefore of hypoxia-de-
pendent genes (e.g., carbonic anhydrase and glucose trans-
porters) [42]. For example, HIF-1 modulates the 
transcription of genes involved in glycolytic metabolism, 
oxygen consumption, survival, angiogenesis, migration 
and invasion. Accordingly, its stabilization has dramatic 
repercussions for the gene expression profile and eventual-
ly the behavior of the tumor cells [2,25]. Moreover, hypoxia 
actively participates in the activation of angiogenesis, by 
regulating the inducers and inhibitors that contribute to it. 
Specifically, tumor hypoxia induces the expression of mol-
ecules that disrupt endothelial and pericyte coverage, such 
as Ang2, which further contributes to the initiation of vas-
cular sprouting. In addition, hypoxia results in the mobili-
zation of multiple types of stem cells from the bone mar-
row and the recruitment of immune cells to the tumor 
microenvironment [7]. 
Recent advances in molecular biology and the study of 
families with hereditary renal cancer (in the setting of von 
Hippel-Lindau, hereditary papillary, Birt-Hogg-Dubé, and 
hereditary leiomyomatosis) have led to the recognition of 
genes and proteins involved in the pathogenesis of several 
tumor entities, and thus of the potential for patient-tailored 
targeted therapy [35,51]. In particular, inactivation of the 
von Hippel-Lindau tumor suppressor gene in patients with 
renal cell carcinoma (RCC) involves the failed degradation 
of HIF1α signaling, even under normoxia, and therefore 
the accumulation of this transcription factor, which results 
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Other recently proposed novel targets
The fibroblast growth factor/fibroblast growth factor receptor 
(FGF/FGFR) signaling axis plays an important role in nor-
mal organ, vascular, and skeletal development. The deregu-
lation of FGF/FGFR signaling through the genetic modifi-
cation or œverexpression of either component has been 
observed in numerous tumors, consistent with the key role 
of FGF/FGFR axis in driving tumor angiogenesis. Preclini-
cal data showed that the inhibition of FGFR signaling 
causes antiproliferative and/or pro-apoptotic effects, both 
in vitro and in vivo, thus confirming the validity of the 
FGF/FGFR axis as a potential therapeutic target [10]. Ac-
cordingly, several drugs against different pro-angiogenic 
targets have been developed for testing [22].
Semaphorins (SEMAs) are a superfamily of secreted or 
membrane-associated glycoproteins that have been impli-
cated in the control of axonal wiring. They are also known 
to be involved in angiogenesis and cancer progression. 
SEMAs positively or negatively modulate many intrinsic 
properties of tumor cells, such as proliferation, cell survival, 
cell adhesion, and tumor invasiveness, but they also act on 
stromal properties, including endothelial cell migration 
VEGF as a prototypical anti-angiogenesis target
Monoclonal antibodies may be direct or indirect acting. Their 
direct action is to block VEGF signaling by blocking the li-
gand or its receptors (VEGFRs) whereas their indirect ac-
tion is mediated by the immune system (complement sys-
tem activation, cytotoxic lymphocytes, and macrophages), 
resulting in tumor-cell destruction. Monoclonal antibodies 
were the first anti-angiogenic drug to demonstrate a clear 
clinical effect, increasing the survival of patients with meta-
static colorectal cancer. The most well known example of 
these drugs is bevacizumab, an antibody against human 
VEGF ligand [28] (Fig. 1).
Selective inhibitors of kinase activity compete with ATP for 
binding to the catalytic domain of the protein, thereby block-
ing kinase activity including that of VEGFRs. Initial tests of 
these drugs as anti-proliferative agents for tumor endothelial 
cells resulted in the development of a large number of inhibi-
tors acting on different pathways and different cell types 
apart from those expressing VEGFRs (promiscuous tyrosine-
kinase inhibition profile). Currently, sunitinib and sorafenib 
are the most widely used drugs of this class since they dem-
onstrate the best anti-angiogenic activity [1] (Fig. 1).
Fig. 1. Therapeutic targets and their angiogenic inhibitors currently used in preclinical and clinical studies. (See text for details). VEGF, vascular endotelial 
growth factor; anti VEFG-Trap, antiangiogenic VEGF-Trap; VEGFR-2, VEGF receptor-2; FGF, fibroblast growth factor; FGFRs, FGFreceptors;  SEMAs, sema-
phorins. (See text for details).
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and survival [11,48]. Thus, the overexpression of Sema3E 
reduces tumor burden by counteracting angiogenesis, but 
it also increases metastatic spread of the tumor. Casazza et 
al explored the pleiotropic therapeutic activities associated 
with an uncleavable Sema3E isoform (Uncl-Sema3E) [16], 
which retains the anti-angiogenic activity of endogenous 
p61-Sema3Ebut also has anti-invasive and anti-metastatic 
effects on the tumor. Similar to p61-Sema3E, Uncl-Sema3E 
binds to PlxnD1 in endothelial cells and induces the ex-
pected SEMA-driven anti-angiogenic collapse of the tumor. 
Furthermore, in tumor cells, the Uncl-Sema3E-PlxnD-
1complex fails to elicit the ErbB2-mediated pro-invasive 
and pro-metastatic pathway. With these results the authors 
proposed Uncl-Sema3E as a novel anti-angiogenic and anti-
metastatic therapeutic approach.
Angiopoietins are growth factors that promote angiogen-
esis and help stabilize the formation of blood vessels from 
pre-existing ones. Ang1 and Ang2 are required for vessel 
maturation, as demonstrated by knock-out studies in mice 
[52]. Moreover, Ang2 is critically associated with tumor an-
giogenesis and progression, cooperating with VEGF and 
Ang1 through Tie2-dependent pathways. In addition, Ang2 
stimulates tumor angiogenesis, invasion, and metastasis 
through Tie2-independent pathways involving integrin-
mediated signaling. Therefore, Ang2 is also an attractive 
therapeutic target, as corroborated in recent studies using a 
neutralizing anti-Ang2 antibody [27].
Clinical results and remaining challenges
Preclinical studies often report positive results regarding 
the efficacy of anti-VEGF therapy, but the results of clini-
cal trials vary depending on the cancer type and anti-an-
giogenic therapy used. Phase III studies have indeed shown 
the benefits of bevacizumab, sunitinib, and other VEGF-
targeted therapies, either as single agents or in combina-
tion with chemotherapy. Blocking the formation of new 
blood vessels with anti-angiogenic therapy is currently 
used to treat certain types of cancers, including metastatic 
RCC [43,44]. Several clinical trials have confirmed the 
positive impact of anti-angiogenic therapies in controlling 
the growth of this typically highly-VEGF secreting tumor 
[19,39,45,46]. Nevertheless, many authors have found 
that anti-angiogenic treatments are more effective in in-
Fig. 2. Mechanisms of resistance to anti-angiogenic therapy: (A) intrinsic resistance (or refractoriness); (B) acquired resistance. Mechanisms of intrinsic 
resistance include the multiplicity of pro-angiogenic factors produced by tumor or stromal cells within the tumor mass and vascular co-option. Mecha-
nisms of acquired resistance include the overexpression of pro-angiogenic factors, the recruitment of vascular progenitor cells (BMDCs), and an increase 
in pericyte coverage. Together, they allow for revascularization despite therapeutic inhibition, and thus tumor regrowth and disease progression. 
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Intrinsic resistance to anti-angiogenic therapy is defined 
as a total lack of response to the therapy; it is characterized 
by tumor indifference, as there is no response to treatment 
(Fig. 2A). IR has been described in patients treated with bev-
acizumab, sorafenib, and sunitinib, as determined by the 
continued growth of their tumors [3,34]. Acquired resistance 
refers to the adaptive capacity of tumors that allows them to 
evade continued therapeutic inhibition of their growth after 
an initial phase of effectiveness. In fact, anti-angiogenic drugs 
achieve clinical efficacy in many patients, but these clinical 
benefits are overshadowed by an apparent acquired resis-
tance. Moreover, some patients do not respond at all to anti-
angiogenic therapy, indicative of intrinsic resistance. 
It has been shown that, from the beginning of their pro-
gression, tumors are capable of expressing multiple pro-
angiogenic factors, which limits the efficacy of anti-VEGF 
therapy since in these cases angiogenesis is only partially 
blocked [23]. Another molecular mechanism that may be 
involved in IR is the de-regulation of the HIF pathway. 
HIF-activated tumors, such as renal tumors, express high 
levels of genes encoding pro-angiogenic molecules con-
trolled by this pathway, thereby reducing the effect of anti-
angiogenic therapy [43,44]. Other potential mechanisms 
supporting tumor growth include an independence from 
angiogenesis, including the co-option of pre-existing ves-
sels, vasculogenic mimicry, mosaic vessels, and the mobili-
zation of latent vessels [50]. 
Could the specific angiogenic features of each tumor 
determine their upfront sensitivity or resistance to anti-an-
giogenic therapy? Interestingly, in astrocytomas, a group of 
highly oxygen-dependent brain tumors, there is a change in 
the mechanism by which they acquire their blood supply. 
Thus, low-grade astrocytomas grow by co-opting pre-exist-
ing, normal brain vessels whereas in the progression from 
grade III to grade IV, in so-called glioblastoma multiforme 
(GBM), the enhanced demand for oxygen and nutrients ac-
tivates an angiogenic program [40]. Recently, the FDA ap-
proved bevacizumab for the treatment of recurrent GBM 
based on several studies demonstrating efficacy in terms of 
increased PFS and OS when the drug is combined with 
conventional chemotherapy. Unfortunately, tumor resis-
tance occurs with new distant foci of progression or diffuse 
in situ infiltration associated or not with local tumor recur-
rence, as shown by fluid-attenuated inversion recovery and 
magnetic resonance imaging analyses [38,54].
In addition to the traditional forms of resistance to some 
drugs, which are acquired by mutations that affect the drug 
target of drugs or entry mechanisms [24], acquired resistance 
(AR) to anti-angiogenic therapies is both indirect and eva-
sive. Typically, alternative mechanisms are created that lead 
to the activation of angiogenesis even when the drug target 
remains inhibited [33]. Tumors have remarkable plasticity 
creasing progression-free survival (PFS) than in prolong-
ing overall survival (OS). However, based on the clear 
clinical benefits, with a remarkable increase in PFS, despite 
the absence of a robust, statistically significant increase in 
OS, VEGF pathway inhibitors are the mainstay of therapy 
in RCC and have been approved by the US Food and Drug 
Administration (FDA) [20,26]. 
The discrepancy between PFS and OS has fueled the con-
troversy of how to best measure the clinical benefits of treat-
ment, because the effects of anti-angiogenic therapies typi-
cally include increased tumor necrosis, as observed in 
imaging studies. Thus, cavitation and the loss of viable tumor 
mass ascribed to anti-VEGF agents may indeed translate into 
an impact on tumor growth but without significant alteration 
of the tumor dimensions, as required by RECIST (Response 
Evaluation Criteria in Solid Tumors) guidelines [18,47]. 
The pattern of growth and the modifications induced at 
the site of tumor development are strongly dependent on 
the tumor type and, in particular, its angiogenic features 
and the pro-angiogenic capacity arising from tumor-stroma 
interactions. This is a crucial consideration, because in cer-
tain cancers, such as RCC and hepatocellular carcinoma 
(HCC), single-agent VEGF-targeted therapy has demon-
strated significant activity whereas in other tumors, such as 
colorectal cancer (CRC), considerably fewer clinical bene-
fits have been obtained and VEGF-targeted therapy is 
therefore administered in combination with chemotherapy. 
In RCC, angiogenesis is presumably highly VEGF-depen-
dent, in part because of its high frequency of inactivation of 
the von Hippel-Landau tumor suppressor gene [53]. The 
same dependence on angiogenesis is presumably the key to 
the efficacy of anti-angiogenic therapy in HCC. These tu-
mors are highly angiogenic in the liver and their growth 
displaces the normal parenchyma. This pattern is in con-
trast to metastatic foci of CRC in the liver, in which case the 
tumors often replace rather than displace the liver paren-
chyma, by the FAS-ligand-induced death of hepatocytes. 
This leads to the co-option of existing blood vessels rather 
than a dependence on sprouting angiogenesis [9,18]. 
Resistance to anti-angiogenic therapy
It was initially assumed that anti-angiogenic therapy does 
not induce resistance, because of its specific targeting of en-
dothelial cells, which do not exhibit genetic instability [8]. 
However, experimental and clinical evidence has shown 
that the benefits of anti-angiogenic therapy are mild and 
transient [44] and that, as in classical chemotherapy and 
radiation, tumor adaptability is also a challenge [14,15]. 
Among tumor responses to therapy, it is essential to distin-
guish between refractoriness, sometimes called intrinsic re-
sistance (IR), and acquired resistance (AR) [18]. 
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ment of the neoplastic lesion but also for the response of the 
tumor to therapeutic inhibition of the VEGF pathway. Togeth-
er with the characteristics of the tumor cells, the stroma con-
tributes to both IR and AR. Indeed, many of the tumor-cell-
dependent mechanisms of resistance are implemented 
through stromal modification, e.g., the recruitment of infil-
trating cells, such as cancer-associated fibroblasts and tu-
mor-associated macrophages, or the production of alterna-
tive pro-angiogenic factors. One of the main modifications 
induced by anti-angiogenic therapy in tumors is the above-
described increase in hypoxia and HIF-1 stabilization. How-
ever, neoplastic cells can become tolerant of hypoxia, and thus 
acquire therapeutic resistance, by modifying their metabolic 
characteristics. Alternatively, they can escape the hypoxic con-
ditions, either alone or sustained by their stromal neighbors.
Perspectives
Overcoming resistance is a crucial step in the development 
of anti-angiogenic therapies. Among the strategies pro-
posed thus far is the use of multi-pathway inhibitors. More-
over, given the plasticity of the response to treatment, ob-
served in preclinical studies, a sequential approach in 
which an anti-angiogenic drug is followed by a non-anti-
angiogenic drug (whether another targeted therapy or che-
motherapy) may resensitize patients to a third-line anti-
angiogenic agent. Obviously, many studies will be needed 
to identify the therapeutic approach that results in maxi-
mum clinical benefit for patients. Furthermore, the role of 
the stroma, in addition to that of the tumor cells, in the 
emergence of resistance to anti-angiogenic therapies has 
important clinical implications and suggests innovative 
treatment perspectives.   
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